Meta Information
ID:glp-1-receptor-agonists
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-21T22:30:00Z
Model
phase-a-upgrade-claude-sonnet-4.6
Interactions
Target id:
/condition/history-of-mtc-or-men2
Target name:
Personal or Family History of Medullary Thyroid Carcinoma (MTC) or MEN 2
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Semaglutide caused thyroid C-cell tumors in animal studies. It is strictly contraindicated in individuals with a personal or family history of these specific thyroid cancers.
Actionable advice:
This medication should not be taken with a personal or family history of MTC or MEN 2.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
CONTRAINDICATIONS WEGOVY is contraindicated in the following conditions: • A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions (5.1)]. • A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in WEGOVY injection or WEGOVY tablet.
Label source:
FDA label: Semaglutide
Action type:
avoid
Target id:
/class/antidiabetic-medications
Target name:
Insulin and Sulfonylureas (Class Wide)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Combining GLP-1 agonists with insulin or sulfonylureas (e.g., glipizide, glyburide) greatly increases the risk of severe hypoglycemia (low blood sugar) due to their complementary mechanisms of lowering glucose.
Actionable advice:
Your doctor must significantly reduce the dose of your insulin or sulfonylurea when starting this medication.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline (semaglutide injection 8.2%, placebo 5.2%) than among patients without a known history of diabetic retinopathy (semaglutide injection 0.7%, placebo 0.4%).
Label source:
FDA label: Semaglutide
Action type:
adjust_with_prescriber
Target id:
/procedure/general-anesthesia
Target name:
Surgery with General Anesthesia
Severity:
major
Interaction type:
adverse
Nature:
temporal
Temporal spacing:
Hours before target:
168
Hours after target:
null
Description:
Semaglutide's delay of gastric emptying significantly increases the risk of pulmonary aspiration of stomach contents during general anesthesia and deep sedation.
Actionable advice:
A surgeon should be informed about semaglutide use; it must be held for at least one week before elective surgery.
Validation status:
validated_via_clinical_guidance
Evidence tier:
tier_b
Evidence basis:
clinical_guidance_verbatim
Evidence anchors:
Exact phrase from label:
the risk of regurgitation and pulmonary aspiration of gastric contents during general anesthesia and deep sedation
Label source:
ASA Consensus Statement (2023): Preoperative Management of Patients on GLP-1 Receptor Agonists
Action type:
informational_none
Target id:
/dietary/alcohol-acute
Target name:
Alcohol (Acute Consumption)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Alcohol can independently lower blood sugar, increasing the risk of hypoglycemia when taken with semaglutide. It can also irritate the pancreas, potentially increasing the risk of pancreatitis.
Actionable advice:
Alcohol consumption should be limited or avoided, and drinking on an empty stomach should never be done while using this medication.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
All GLP-1RA did not lead to increased incidence of hypoglycemia.
Label source:
PubMed: Frontiers in endocrinology (2023)
Source url:
Exact phrase from label:
GLP-1 RAs use does not increase AP risk is associated with lower complications in those who developed AP and linked with lower all-cause mortality in patients with T2DM.
Label source:
PubMed: The American journal of gastroenterology (2026)
Source url:
Exact phrase from label:
GLP-1RAs are associated with a modest but statistically significant increase in the risk of AP and pancreatic cancer compared to DPP-4i.
Label source:
PubMed: American journal of medicine open (2025)
Action type:
separate
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Based on animal studies, there may be potential risks to the fetus. It is recommended to discontinue semaglutide at least 2 months before a planned pregnancy.
Actionable advice:
This should not be used during pregnancy and should be discontinued at least 2 months before attempting to conceive.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
pregnancy
Label source:
FDA label: Semaglutide
Action type:
avoid
Target id:
/condition/history-of-pancreatitis
Target name:
History of Pancreatitis
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
GLP-1 receptor agonists, including semaglutide, have been associated with an increased risk of acute pancreatitis. Use is cautioned in patients with a prior history.
Actionable advice:
A doctor should be informed of any history of pancreatitis before starting, and any severe abdominal pain should be reported immediately.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Acute Pancreatitis: Has been observed in patients
Label source:
FDA label: Semaglutide (Wegovy) — Warnings and Precautions (5.2) Acute Pancreatitis
Action type:
monitor
Target id:
/condition/severe-gastroparesis
Target name:
Severe Gastroparesis
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Semaglutide's primary mechanism is to delay gastric emptying. In individuals who already have this condition (gastroparesis), it can cause a severe worsening of symptoms.
Actionable advice:
This medication is generally contraindicated for individuals with pre-existing severe gastroparesis.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
WEGOVY is not recommended in patients with severe gastroparesis.
Label source:
FDA label: Semaglutide
Action type:
avoid
Target id:
/dietary/meal
Target name:
Any Food, Beverage, or Other Oral Medication (for Oral Semaglutide)
Severity:
major
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
0.5
Hours after target:
null
Description:
For the oral formulation (Rybelsus), absorption is drastically reduced by food, beverages, or other medications. This interaction does not apply to the injectable form.
Actionable advice:
If taking oral semaglutide, you must wait at least 30 minutes after your dose before eating, drinking, or taking other oral pills.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
After taking a WEGOVY tablet, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications [see Clinical Pharmacology (12.3)].
Label source:
FDA label: Semaglutide
Action type:
informational_none
Target id:
/class/oral-medications-general
Target name:
Oral Medications (General) (Class Wide)
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
GLP-1 agonists significantly slow stomach emptying, which can delay the absorption and reduce the peak concentration of many oral medications, potentially affecting their efficacy.
Actionable advice:
It is important to talk to a doctor about the timing of all oral medications, especially those with a narrow therapeutic window.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
WEGOVY causes a delay of gastric emptying and thereby has the potential to impact the absorption
Label source:
FDA label: Semaglutide (Wegovy) — Drug Interactions (7.2) Oral Medications
Action type:
informational_none
Target id:
/condition/renal-impairment
Target name:
Renal Impairment
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Gastrointestinal side effects can lead to dehydration, which can cause or worsen kidney problems. Caution is advised in patients with pre-existing renal impairment.
Actionable advice:
Adequate hydration is a good idea, and any decrease in urination is worth reporting to a doctor; regular kidney function monitoring is advised.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Acute Kidney Injury Due to Volume Depletion
Label source:
FDA label: Semaglutide (Wegovy) — Warnings and Precautions (5.5) Acute Kidney Injury Due to Volume Depletion
Action type:
monitor
Target id:
/condition/diabetic-retinopathy
Target name:
Diabetic Retinopathy
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. This has been observed in trials with semaglutide.
Actionable advice:
If you have a history of diabetic retinopathy, ensure regular eye exams after starting this medication.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline (semaglutide injection 8.2%, placebo 5.2%) than among patients without a known history of diabetic retinopathy (semaglutide injection 0.7%, placebo 0.4%).
Label source:
FDA label: Semaglutide
Action type:
informational_none
Target id:
/dietary/high-fat-meal
Target name:
High-Fat or Greasy Meals (Semaglutide Specific)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
High-fat foods naturally slow stomach emptying. Consuming them while on semaglutide can significantly worsen side effects like nausea, bloating, and abdominal discomfort.
Actionable advice:
Large, high-fat, or greasy meals are best avoided to minimize gastrointestinal side effects.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Pharmacologically mediated, marked initial maternal body weight loss and reductions in body weight gain and food consumption coincided with the occurrence of sporadic abnormalities (vertebra, sternebra, ribs) at greater than or equal to 0.075 mg/kg twice weekly (greater than or equal to 2 times human exposure).
Label source:
FDA label: Semaglutide
Action type:
avoid
Target id:
/class/estrogens
Target name:
Oral Contraceptives
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Semaglutide's delay of stomach emptying may reduce the absorption and effectiveness of oral hormonal contraceptives.
Actionable advice:
Consider using a non-oral or barrier method of contraception while on semaglutide, or discuss options with your doctor.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
significant changes in exposure were observed for oral contraceptives and levothyroxine following the administration of tirzepatide and oral semaglutide
Label source:
Min JS et al., Drug Des Devel Ther 2024: Comprehensive Review on PK and DDIs of Approved GLP-1 RAs
Action type:
informational_none
Target id:
/intervention/levothyroxine
Target name:
Levothyroxine
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Delayed gastric emptying caused by semaglutide can alter the absorption of levothyroxine, potentially affecting thyroid hormone levels.
Actionable advice:
Thyroid function tests (TSH) should be monitored regularly after starting or changing the dose of semaglutide.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Density Associated with Thyroid Hormone Over-Replacement Increased bone resorption and decreased bone mineral density may occur as a result of levothyroxine over-replacement, particularly in post-menopausal women.
Label source:
FDA label: Levothyroxine (target-side evidence)
Action type:
monitor
Target id:
/intervention/warfarin
Target name:
Warfarin
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Altered absorption due to delayed gastric emptying can affect warfarin levels, potentially changing bleeding risk. Increased monitoring of INR is recommended.
Actionable advice:
INR should be monitored more frequently when starting or adjusting the semaglutide dose.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Because bleeding risk is increased when these drugs are used concomitantly with warfarin, closely monitor patients receiving any such drug with warfarin.
Label source:
FDA label: Warfarin (target-side evidence)
Action type:
monitor
Target id:
/condition/dehydration
Target name:
Dehydration
Severity:
moderate
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Semaglutide can cause nausea, vomiting, or diarrhea, leading to fluid loss. Maintaining hydration is critical to prevent acute kidney injury.
Actionable advice:
Adequate hydration is best maintained by drinking plenty of fluids, especially if GI side effects occur.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
In addition, 2 patients treated with WEGOVY had acute kidney injury with dehydration in other clinical trials.
Label source:
FDA label: Semaglutide
Action type:
informational_none
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
It is not known whether semaglutide passes into human breast milk. A decision should be made whether to discontinue nursing or to discontinue the drug.
Actionable advice:
It is important to talk to a doctor about the risks and benefits before using while breastfeeding.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
om a clinical lactation study with semaglutide oral tablet formulation reported semaglutide concentrations below the lower limit of quantification in human milk.
Label source:
FDA label: Semaglutide
Action type:
informational_none
Target id:
/intervention/berberine
Target name:
Berberine
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Berberine also lowers blood glucose, and taking it with semaglutide can lead to an additive effect, increasing the risk of hypoglycemia.
Actionable advice:
Blood glucose is best monitored closely if combining these, and the combination is best avoided in those prone to low blood sugar.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Metabolically, fasting insulin, FBS, and HOMA-IR decreased significantly in the berberine group but not in the control group, with crude and adjusted between-group differences remaining significant.
Label source:
PubMed: Adjunctive berberine improves hormonal, metabolic, and inflammatory profiles in women with polycystic ovary syndrome: a retrospective case-control study. (PMID 42255444)
Action type:
avoid
Target id:
/class/viscous-fibers
Target name:
Viscous Soluble Fibers (e.g., Psyllium, Glucomannan)
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
High doses of gel-forming fibers can further slow gastric transit, potentially worsening gastrointestinal side effects of semaglutide like bloating, gas, or constipation.
Actionable advice:
Introduce fiber supplements slowly and ensure adequate fluid intake to minimize potential GI discomfort.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Overall gastric emptying was similar to that with placebo; however, the observed first-hour delay with semaglutide may contribute to a slower entry of glucose into the circulation.
Label source:
Adv Nutr review (2024): GLP-1 Receptor Agonists and High-Fiber Diet
Action type:
informational_none
Target id:
/biomarker/amylase-lipase
Target name:
Amylase and Lipase
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Semaglutide can cause asymptomatic increases in serum amylase and lipase. Significant elevations could be a sign of pancreatitis.
Actionable advice:
These lab values may be elevated; reporting any severe abdominal pain to a doctor is worthwhile regardless of lab results.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
mean increase from baseline in amylase of 15% to 16% and lipase of 39%
Label source:
FDA label: Semaglutide (Wegovy) — Adverse Reactions: Amylase and Lipase
Action type:
monitor
Target id:
/biomarker/calcitonin
Target name:
Serum Calcitonin
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Semaglutide can cause dose-dependent and treatment-duration-dependent increases in serum calcitonin, a biomarker for Medullary Thyroid Carcinoma (MTC).
Actionable advice:
The clinical significance of small increases is unknown, but persistently high levels may warrant further evaluation.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with WEGOVY.
Label source:
FDA label: Semaglutide
Action type:
monitor
Target id:
/class/glp-1-receptor-agonists
Target name:
Other GLP-1 Receptor Agonists
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Using more than one GLP-1 receptor agonist (e.g., semaglutide and liraglutide) at the same time is duplicative therapy, provides no additional benefit, and significantly increases the risk of side effects.
Actionable advice:
More than one medication from this class should never be used at the same time.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended
Label source:
Action type:
avoid
Target id:
/class/glucose-lowering-supplements
Target name:
Glucose-Lowering Supplements (e.g., Berberine)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Supplements like berberine, cinnamon, or alpha-lipoic acid can have additive glucose-lowering effects, increasing the risk of hypoglycemia.
Actionable advice:
Blood sugar should be monitored carefully if these supplements are used, and being prepared to treat low blood sugar is advisable.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Moreover, PIO can be preferentially considered when additional glucose-lowering agent is required in DPN patients treated with ALA.
Label source:
PubMed: The neuroprotective benefit from pioglitazone (PIO) addition on the alpha lipoic acid (ALA)-based treatment in experimental diabetic rats. (PMID 24532138)
Action type:
monitor
Target id:
/class/anticholinergic-medications
Target name:
Anticholinergic Medications
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Both GLP-1 agonists and anticholinergic drugs slow down gut motility. Using them together can lead to severe constipation, abdominal distention, or ileus.
Actionable advice:
This combination is best used with caution, and it is important to promptly report any severe constipation or abdominal pain to a doctor.
Validation status:
validated_via_expert_review
Evidence tier:
tier_c
Evidence basis:
expert_review_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
constipation
Label source:
FDA label: GLP-1 receptor agonists (class)
Action type:
monitor
Target id:
/class/dpp4-inhibitors
Target name:
DPP-4 Inhibitors
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Both drug classes work on the incretin system. Combining them provides little additional glycemic benefit while increasing the risk of side effects and cost.
Actionable advice:
Concurrent use is not recommended; one of these medications should typically be discontinued.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
sitagliptin caused an increase in dulaglutide AUC and Cmax
Label source:
Action type:
avoid
Target id:
/dietary/balanced-low-calorie-diet
Target name:
Balanced, Reduced-Calorie Diet
Severity:
major
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
The appetite-suppressing and metabolic effects of GLP-1 agonists are most effective for weight loss when combined with a structured, nutrient-dense, reduced-calorie diet.
Actionable advice:
Follow a healthy, reduced-calorie eating plan to maximize the weight loss and metabolic benefits of the medication.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
in combination with a reduced calorie diet and increased physical activity
Label source:
Action type:
informational_none
Target id:
/intervention/exercise
Target name:
Exercise
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Exercise improves insulin sensitivity and contributes to weight loss, enhancing the metabolic benefits of GLP-1 receptor agonists.
Actionable advice:
This medication is best combined with a regular exercise routine for optimal results in weight and glucose management.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
in combination with a reduced-calorie diet and increased physical activity
Label source:
Action type:
informational_none
Target id:
/condition/medullary-thyroid-carcinoma-history
Target name:
Personal or Family History of Medullary Thyroid Carcinoma (MTC) or MEN 2
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
GLP-1 agonists caused thyroid C-cell tumors in animal studies, leading to a strict contraindication for individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Actionable advice:
This medication should not be used with a personal or direct-family history of MTC or MEN 2 syndrome.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Labeled boxed contraindication: GLP-1 receptor agonists caused thyroid C-cell (medullary) tumors in rodents and are contraindicated in patients with a personal/family history of medullary thyroid carcinoma or MEN 2. Class-wide labeling.
Label source:
Class inference
Action type:
avoid
Target id:
/condition/gastroparesis
Target name:
Severe Gastroparesis
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
These medications work by delaying gastric emptying, which will significantly worsen the symptoms of pre-existing severe gastroparesis (delayed stomach emptying).
Actionable advice:
This medication should be avoided with a diagnosis of severe gastroparesis.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Established mechanism: GLP-1 receptor agonists delay gastric emptying, which can markedly worsen pre-existing severe gastroparesis; use is cautioned/avoided. Labeled effect.
Label source:
Class inference
Action type:
avoid